Literature DB >> 32559452

Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?

T P Afra1, Muhammed Razmi T2, Anuradha Bishnoi3, Na Bishurul Hafi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32559452      PMCID： PMC7832625          DOI： 10.1016/S1473-3099(20)30472-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  6 in total

1.  Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.

Authors:  Taneisha K McGhie; Paula Harvey; Jiandong Su; Nicole Anderson; George Tomlinson; Zahi Touma
Journal:  Clin Exp Rheumatol       Date:  2018-04-13       Impact factor: 4.473

2.  Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.

Authors:  Samya Mohammad; Megan E B Clowse; Amanda M Eudy; Lisa G Criscione-Schreiber
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-09       Impact factor: 4.794

Review 3.  Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.

Authors:  Ilan Youngster; Lidia Arcavi; Renata Schechmaster; Yulia Akayzen; Hen Popliski; Janna Shimonov; Svetlana Beig; Matitiahu Berkovitch
Journal:  Drug Saf       Date:  2010-09-01       Impact factor: 5.228

4.  Hydroxychloroquine prophylaxis for COVID-19 contacts in India.

Authors:  Sahaj Rathi; Pranav Ish; Ashwini Kalantri; Shriprakash Kalantri
Journal:  Lancet Infect Dis       Date:  2020-04-17       Impact factor: 25.071

5.  The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis.

Authors:  Jing-Wei Li; Tian-Wen Han; Mark Woodward; Craig S Anderson; Hao Zhou; Yun-Dai Chen; Bruce Neal
Journal:  Prog Cardiovasc Dis       Date:  2020-04-16       Impact factor: 8.194

6.  Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).

Authors:  John R Giudicessi; Peter A Noseworthy; Paul A Friedman; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2020-04-07       Impact factor: 7.616
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.